Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms

Journal of Psychopharmacology

Volumn 16, Issue 3, 2002, Pages 271-272

  Curtin, Francois ^a   Berney, Patricia ^a   Kaufmann, Christophe ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antidepressant; Discontinuation syndrome; MAOI; Moclobemide; SSRI

Indexed keywords

ANTIDEPRESSANT AGENT; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGITATION; ANXIETY; ARTICLE; ATAXIA; CASE REPORT; CLINICAL FEATURE; COGNITIVE DEFECT; DRUG DISCONTINUATION SYNDROME; DRUG HALF LIFE; FEMALE; FLU LIKE SYNDROME; HUMAN; INSOMNIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYNDROME;

DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFLUENZA, HUMAN; LONG-TERM CARE; MIDDLE AGED; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0036726910     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988110201600314     Document Type: Article

References (9)

1. Differential changes in brain and platelet 5-HAT concentrations after steady-state achievement and repeated administration of antidepressant drugs in mice
2. Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria
3. Pre-clinical pharmacology of moclobemide. A review of published studies
4. Serotonin reuptake inhibitor withdrawal
5. Withdrawal phenomena associated with antidepressant and antipsychotic agents
6. Antidepressant discontinuation syndromes. Clinical relevance, prevention and management
7. Moclobemide safety: Monitoring a newly developed product in the 1990s
8. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: Focus on moclobemide
9. Moclobemide for anxiety disorders: A focus on moclobemide for panic disorder